From: Agnibho Mondal Date: Sat, 10 Dec 2016 01:53:24 +0000 (+0530) Subject: Initial commit X-Git-Url: https://code.agnibho.com/repo?p=pdosage.git;a=commitdiff_plain;h=f964a699931e53a090d411a869ef4ee4d0543f5d Initial commit --- f964a699931e53a090d411a869ef4ee4d0543f5d diff --git a/.babelrc b/.babelrc new file mode 100644 index 0000000..9897749 --- /dev/null +++ b/.babelrc @@ -0,0 +1,5 @@ +{ + "presets": [ + ["es2015", { "modules": false }] + ] +} diff --git a/.gitignore b/.gitignore new file mode 100644 index 0000000..af1f85f --- /dev/null +++ b/.gitignore @@ -0,0 +1,6 @@ +.DS_Store +node_modules/ +dist/ +npm-debug.log +todo.org +src/dosage.json \ No newline at end of file diff --git a/LICENSE.txt b/LICENSE.txt new file mode 100644 index 0000000..94a9ed0 --- /dev/null +++ b/LICENSE.txt @@ -0,0 +1,674 @@ + GNU GENERAL PUBLIC LICENSE + Version 3, 29 June 2007 + + Copyright (C) 2007 Free Software Foundation, Inc. + Everyone is permitted to copy and distribute verbatim copies + of this license document, but changing it is not allowed. + + Preamble + + The GNU General Public License is a free, copyleft license for +software and other kinds of works. + + The licenses for most software and other practical works are designed +to take away your freedom to share and change the works. By contrast, +the GNU General Public License is intended to guarantee your freedom to +share and change all versions of a program--to make sure it remains free +software for all its users. We, the Free Software Foundation, use the +GNU General Public License for most of our software; it applies also to +any other work released this way by its authors. You can apply it to +your programs, too. + + When we speak of free software, we are referring to freedom, not +price. Our General Public Licenses are designed to make sure that you +have the freedom to distribute copies of free software (and charge for +them if you wish), that you receive source code or can get it if you +want it, that you can change the software or use pieces of it in new +free programs, and that you know you can do these things. + + To protect your rights, we need to prevent others from denying you +these rights or asking you to surrender the rights. Therefore, you have +certain responsibilities if you distribute copies of the software, or if +you modify it: responsibilities to respect the freedom of others. + + For example, if you distribute copies of such a program, whether +gratis or for a fee, you must pass on to the recipients the same +freedoms that you received. You must make sure that they, too, receive +or can get the source code. And you must show them these terms so they +know their rights. + + Developers that use the GNU GPL protect your rights with two steps: +(1) assert copyright on the software, and (2) offer you this License +giving you legal permission to copy, distribute and/or modify it. + + For the developers' and authors' protection, the GPL clearly explains +that there is no warranty for this free software. For both users' and +authors' sake, the GPL requires that modified versions be marked as +changed, so that their problems will not be attributed erroneously to +authors of previous versions. + + Some devices are designed to deny users access to install or run +modified versions of the software inside them, although the manufacturer +can do so. This is fundamentally incompatible with the aim of +protecting users' freedom to change the software. The systematic +pattern of such abuse occurs in the area of products for individuals to +use, which is precisely where it is most unacceptable. Therefore, we +have designed this version of the GPL to prohibit the practice for those +products. If such problems arise substantially in other domains, we +stand ready to extend this provision to those domains in future versions +of the GPL, as needed to protect the freedom of users. + + Finally, every program is threatened constantly by software patents. +States should not allow patents to restrict development and use of +software on general-purpose computers, but in those that do, we wish to +avoid the special danger that patents applied to a free program could +make it effectively proprietary. To prevent this, the GPL assures that +patents cannot be used to render the program non-free. + + The precise terms and conditions for copying, distribution and +modification follow. + + TERMS AND CONDITIONS + + 0. Definitions. + + "This License" refers to version 3 of the GNU General Public License. + + "Copyright" also means copyright-like laws that apply to other kinds of +works, such as semiconductor masks. + + "The Program" refers to any copyrightable work licensed under this +License. Each licensee is addressed as "you". "Licensees" and +"recipients" may be individuals or organizations. + + To "modify" a work means to copy from or adapt all or part of the work +in a fashion requiring copyright permission, other than the making of an +exact copy. The resulting work is called a "modified version" of the +earlier work or a work "based on" the earlier work. + + A "covered work" means either the unmodified Program or a work based +on the Program. + + To "propagate" a work means to do anything with it that, without +permission, would make you directly or secondarily liable for +infringement under applicable copyright law, except executing it on a +computer or modifying a private copy. Propagation includes copying, +distribution (with or without modification), making available to the +public, and in some countries other activities as well. + + To "convey" a work means any kind of propagation that enables other +parties to make or receive copies. Mere interaction with a user through +a computer network, with no transfer of a copy, is not conveying. + + An interactive user interface displays "Appropriate Legal Notices" +to the extent that it includes a convenient and prominently visible +feature that (1) displays an appropriate copyright notice, and (2) +tells the user that there is no warranty for the work (except to the +extent that warranties are provided), that licensees may convey the +work under this License, and how to view a copy of this License. If +the interface presents a list of user commands or options, such as a +menu, a prominent item in the list meets this criterion. + + 1. Source Code. + + The "source code" for a work means the preferred form of the work +for making modifications to it. "Object code" means any non-source +form of a work. + + A "Standard Interface" means an interface that either is an official +standard defined by a recognized standards body, or, in the case of +interfaces specified for a particular programming language, one that +is widely used among developers working in that language. + + The "System Libraries" of an executable work include anything, other +than the work as a whole, that (a) is included in the normal form of +packaging a Major Component, but which is not part of that Major +Component, and (b) serves only to enable use of the work with that +Major Component, or to implement a Standard Interface for which an +implementation is available to the public in source code form. A +"Major Component", in this context, means a major essential component +(kernel, window system, and so on) of the specific operating system +(if any) on which the executable work runs, or a compiler used to +produce the work, or an object code interpreter used to run it. + + The "Corresponding Source" for a work in object code form means all +the source code needed to generate, install, and (for an executable +work) run the object code and to modify the work, including scripts to +control those activities. However, it does not include the work's +System Libraries, or general-purpose tools or generally available free +programs which are used unmodified in performing those activities but +which are not part of the work. For example, Corresponding Source +includes interface definition files associated with source files for +the work, and the source code for shared libraries and dynamically +linked subprograms that the work is specifically designed to require, +such as by intimate data communication or control flow between those +subprograms and other parts of the work. + + The Corresponding Source need not include anything that users +can regenerate automatically from other parts of the Corresponding +Source. + + The Corresponding Source for a work in source code form is that +same work. + + 2. Basic Permissions. + + All rights granted under this License are granted for the term of +copyright on the Program, and are irrevocable provided the stated +conditions are met. This License explicitly affirms your unlimited +permission to run the unmodified Program. The output from running a +covered work is covered by this License only if the output, given its +content, constitutes a covered work. This License acknowledges your +rights of fair use or other equivalent, as provided by copyright law. + + You may make, run and propagate covered works that you do not +convey, without conditions so long as your license otherwise remains +in force. You may convey covered works to others for the sole purpose +of having them make modifications exclusively for you, or provide you +with facilities for running those works, provided that you comply with +the terms of this License in conveying all material for which you do +not control copyright. Those thus making or running the covered works +for you must do so exclusively on your behalf, under your direction +and control, on terms that prohibit them from making any copies of +your copyrighted material outside their relationship with you. + + Conveying under any other circumstances is permitted solely under +the conditions stated below. Sublicensing is not allowed; section 10 +makes it unnecessary. + + 3. Protecting Users' Legal Rights From Anti-Circumvention Law. + + No covered work shall be deemed part of an effective technological +measure under any applicable law fulfilling obligations under article +11 of the WIPO copyright treaty adopted on 20 December 1996, or +similar laws prohibiting or restricting circumvention of such +measures. + + When you convey a covered work, you waive any legal power to forbid +circumvention of technological measures to the extent such circumvention +is effected by exercising rights under this License with respect to +the covered work, and you disclaim any intention to limit operation or +modification of the work as a means of enforcing, against the work's +users, your or third parties' legal rights to forbid circumvention of +technological measures. + + 4. Conveying Verbatim Copies. + + You may convey verbatim copies of the Program's source code as you +receive it, in any medium, provided that you conspicuously and +appropriately publish on each copy an appropriate copyright notice; +keep intact all notices stating that this License and any +non-permissive terms added in accord with section 7 apply to the code; +keep intact all notices of the absence of any warranty; and give all +recipients a copy of this License along with the Program. + + You may charge any price or no price for each copy that you convey, +and you may offer support or warranty protection for a fee. + + 5. Conveying Modified Source Versions. + + You may convey a work based on the Program, or the modifications to +produce it from the Program, in the form of source code under the +terms of section 4, provided that you also meet all of these conditions: + + a) The work must carry prominent notices stating that you modified + it, and giving a relevant date. + + b) The work must carry prominent notices stating that it is + released under this License and any conditions added under section + 7. This requirement modifies the requirement in section 4 to + "keep intact all notices". + + c) You must license the entire work, as a whole, under this + License to anyone who comes into possession of a copy. This + License will therefore apply, along with any applicable section 7 + additional terms, to the whole of the work, and all its parts, + regardless of how they are packaged. This License gives no + permission to license the work in any other way, but it does not + invalidate such permission if you have separately received it. + + d) If the work has interactive user interfaces, each must display + Appropriate Legal Notices; however, if the Program has interactive + interfaces that do not display Appropriate Legal Notices, your + work need not make them do so. + + A compilation of a covered work with other separate and independent +works, which are not by their nature extensions of the covered work, +and which are not combined with it such as to form a larger program, +in or on a volume of a storage or distribution medium, is called an +"aggregate" if the compilation and its resulting copyright are not +used to limit the access or legal rights of the compilation's users +beyond what the individual works permit. Inclusion of a covered work +in an aggregate does not cause this License to apply to the other +parts of the aggregate. + + 6. Conveying Non-Source Forms. + + You may convey a covered work in object code form under the terms +of sections 4 and 5, provided that you also convey the +machine-readable Corresponding Source under the terms of this License, +in one of these ways: + + a) Convey the object code in, or embodied in, a physical product + (including a physical distribution medium), accompanied by the + Corresponding Source fixed on a durable physical medium + customarily used for software interchange. + + b) Convey the object code in, or embodied in, a physical product + (including a physical distribution medium), accompanied by a + written offer, valid for at least three years and valid for as + long as you offer spare parts or customer support for that product + model, to give anyone who possesses the object code either (1) a + copy of the Corresponding Source for all the software in the + product that is covered by this License, on a durable physical + medium customarily used for software interchange, for a price no + more than your reasonable cost of physically performing this + conveying of source, or (2) access to copy the + Corresponding Source from a network server at no charge. + + c) Convey individual copies of the object code with a copy of the + written offer to provide the Corresponding Source. This + alternative is allowed only occasionally and noncommercially, and + only if you received the object code with such an offer, in accord + with subsection 6b. + + d) Convey the object code by offering access from a designated + place (gratis or for a charge), and offer equivalent access to the + Corresponding Source in the same way through the same place at no + further charge. You need not require recipients to copy the + Corresponding Source along with the object code. If the place to + copy the object code is a network server, the Corresponding Source + may be on a different server (operated by you or a third party) + that supports equivalent copying facilities, provided you maintain + clear directions next to the object code saying where to find the + Corresponding Source. Regardless of what server hosts the + Corresponding Source, you remain obligated to ensure that it is + available for as long as needed to satisfy these requirements. + + e) Convey the object code using peer-to-peer transmission, provided + you inform other peers where the object code and Corresponding + Source of the work are being offered to the general public at no + charge under subsection 6d. + + A separable portion of the object code, whose source code is excluded +from the Corresponding Source as a System Library, need not be +included in conveying the object code work. + + A "User Product" is either (1) a "consumer product", which means any +tangible personal property which is normally used for personal, family, +or household purposes, or (2) anything designed or sold for incorporation +into a dwelling. In determining whether a product is a consumer product, +doubtful cases shall be resolved in favor of coverage. For a particular +product received by a particular user, "normally used" refers to a +typical or common use of that class of product, regardless of the status +of the particular user or of the way in which the particular user +actually uses, or expects or is expected to use, the product. A product +is a consumer product regardless of whether the product has substantial +commercial, industrial or non-consumer uses, unless such uses represent +the only significant mode of use of the product. + + "Installation Information" for a User Product means any methods, +procedures, authorization keys, or other information required to install +and execute modified versions of a covered work in that User Product from +a modified version of its Corresponding Source. The information must +suffice to ensure that the continued functioning of the modified object +code is in no case prevented or interfered with solely because +modification has been made. + + If you convey an object code work under this section in, or with, or +specifically for use in, a User Product, and the conveying occurs as +part of a transaction in which the right of possession and use of the +User Product is transferred to the recipient in perpetuity or for a +fixed term (regardless of how the transaction is characterized), the +Corresponding Source conveyed under this section must be accompanied +by the Installation Information. But this requirement does not apply +if neither you nor any third party retains the ability to install +modified object code on the User Product (for example, the work has +been installed in ROM). + + The requirement to provide Installation Information does not include a +requirement to continue to provide support service, warranty, or updates +for a work that has been modified or installed by the recipient, or for +the User Product in which it has been modified or installed. Access to a +network may be denied when the modification itself materially and +adversely affects the operation of the network or violates the rules and +protocols for communication across the network. + + Corresponding Source conveyed, and Installation Information provided, +in accord with this section must be in a format that is publicly +documented (and with an implementation available to the public in +source code form), and must require no special password or key for +unpacking, reading or copying. + + 7. Additional Terms. + + "Additional permissions" are terms that supplement the terms of this +License by making exceptions from one or more of its conditions. +Additional permissions that are applicable to the entire Program shall +be treated as though they were included in this License, to the extent +that they are valid under applicable law. If additional permissions +apply only to part of the Program, that part may be used separately +under those permissions, but the entire Program remains governed by +this License without regard to the additional permissions. + + When you convey a copy of a covered work, you may at your option +remove any additional permissions from that copy, or from any part of +it. (Additional permissions may be written to require their own +removal in certain cases when you modify the work.) You may place +additional permissions on material, added by you to a covered work, +for which you have or can give appropriate copyright permission. + + Notwithstanding any other provision of this License, for material you +add to a covered work, you may (if authorized by the copyright holders of +that material) supplement the terms of this License with terms: + + a) Disclaiming warranty or limiting liability differently from the + terms of sections 15 and 16 of this License; or + + b) Requiring preservation of specified reasonable legal notices or + author attributions in that material or in the Appropriate Legal + Notices displayed by works containing it; or + + c) Prohibiting misrepresentation of the origin of that material, or + requiring that modified versions of such material be marked in + reasonable ways as different from the original version; or + + d) Limiting the use for publicity purposes of names of licensors or + authors of the material; or + + e) Declining to grant rights under trademark law for use of some + trade names, trademarks, or service marks; or + + f) Requiring indemnification of licensors and authors of that + material by anyone who conveys the material (or modified versions of + it) with contractual assumptions of liability to the recipient, for + any liability that these contractual assumptions directly impose on + those licensors and authors. + + All other non-permissive additional terms are considered "further +restrictions" within the meaning of section 10. If the Program as you +received it, or any part of it, contains a notice stating that it is +governed by this License along with a term that is a further +restriction, you may remove that term. If a license document contains +a further restriction but permits relicensing or conveying under this +License, you may add to a covered work material governed by the terms +of that license document, provided that the further restriction does +not survive such relicensing or conveying. + + If you add terms to a covered work in accord with this section, you +must place, in the relevant source files, a statement of the +additional terms that apply to those files, or a notice indicating +where to find the applicable terms. + + Additional terms, permissive or non-permissive, may be stated in the +form of a separately written license, or stated as exceptions; +the above requirements apply either way. + + 8. Termination. + + You may not propagate or modify a covered work except as expressly +provided under this License. Any attempt otherwise to propagate or +modify it is void, and will automatically terminate your rights under +this License (including any patent licenses granted under the third +paragraph of section 11). + + However, if you cease all violation of this License, then your +license from a particular copyright holder is reinstated (a) +provisionally, unless and until the copyright holder explicitly and +finally terminates your license, and (b) permanently, if the copyright +holder fails to notify you of the violation by some reasonable means +prior to 60 days after the cessation. + + Moreover, your license from a particular copyright holder is +reinstated permanently if the copyright holder notifies you of the +violation by some reasonable means, this is the first time you have +received notice of violation of this License (for any work) from that +copyright holder, and you cure the violation prior to 30 days after +your receipt of the notice. + + Termination of your rights under this section does not terminate the +licenses of parties who have received copies or rights from you under +this License. If your rights have been terminated and not permanently +reinstated, you do not qualify to receive new licenses for the same +material under section 10. + + 9. Acceptance Not Required for Having Copies. + + You are not required to accept this License in order to receive or +run a copy of the Program. Ancillary propagation of a covered work +occurring solely as a consequence of using peer-to-peer transmission +to receive a copy likewise does not require acceptance. However, +nothing other than this License grants you permission to propagate or +modify any covered work. These actions infringe copyright if you do +not accept this License. Therefore, by modifying or propagating a +covered work, you indicate your acceptance of this License to do so. + + 10. Automatic Licensing of Downstream Recipients. + + Each time you convey a covered work, the recipient automatically +receives a license from the original licensors, to run, modify and +propagate that work, subject to this License. You are not responsible +for enforcing compliance by third parties with this License. + + An "entity transaction" is a transaction transferring control of an +organization, or substantially all assets of one, or subdividing an +organization, or merging organizations. If propagation of a covered +work results from an entity transaction, each party to that +transaction who receives a copy of the work also receives whatever +licenses to the work the party's predecessor in interest had or could +give under the previous paragraph, plus a right to possession of the +Corresponding Source of the work from the predecessor in interest, if +the predecessor has it or can get it with reasonable efforts. + + You may not impose any further restrictions on the exercise of the +rights granted or affirmed under this License. For example, you may +not impose a license fee, royalty, or other charge for exercise of +rights granted under this License, and you may not initiate litigation +(including a cross-claim or counterclaim in a lawsuit) alleging that +any patent claim is infringed by making, using, selling, offering for +sale, or importing the Program or any portion of it. + + 11. Patents. + + A "contributor" is a copyright holder who authorizes use under this +License of the Program or a work on which the Program is based. The +work thus licensed is called the contributor's "contributor version". + + A contributor's "essential patent claims" are all patent claims +owned or controlled by the contributor, whether already acquired or +hereafter acquired, that would be infringed by some manner, permitted +by this License, of making, using, or selling its contributor version, +but do not include claims that would be infringed only as a +consequence of further modification of the contributor version. For +purposes of this definition, "control" includes the right to grant +patent sublicenses in a manner consistent with the requirements of +this License. + + Each contributor grants you a non-exclusive, worldwide, royalty-free +patent license under the contributor's essential patent claims, to +make, use, sell, offer for sale, import and otherwise run, modify and +propagate the contents of its contributor version. + + In the following three paragraphs, a "patent license" is any express +agreement or commitment, however denominated, not to enforce a patent +(such as an express permission to practice a patent or covenant not to +sue for patent infringement). To "grant" such a patent license to a +party means to make such an agreement or commitment not to enforce a +patent against the party. + + If you convey a covered work, knowingly relying on a patent license, +and the Corresponding Source of the work is not available for anyone +to copy, free of charge and under the terms of this License, through a +publicly available network server or other readily accessible means, +then you must either (1) cause the Corresponding Source to be so +available, or (2) arrange to deprive yourself of the benefit of the +patent license for this particular work, or (3) arrange, in a manner +consistent with the requirements of this License, to extend the patent +license to downstream recipients. "Knowingly relying" means you have +actual knowledge that, but for the patent license, your conveying the +covered work in a country, or your recipient's use of the covered work +in a country, would infringe one or more identifiable patents in that +country that you have reason to believe are valid. + + If, pursuant to or in connection with a single transaction or +arrangement, you convey, or propagate by procuring conveyance of, a +covered work, and grant a patent license to some of the parties +receiving the covered work authorizing them to use, propagate, modify +or convey a specific copy of the covered work, then the patent license +you grant is automatically extended to all recipients of the covered +work and works based on it. + + A patent license is "discriminatory" if it does not include within +the scope of its coverage, prohibits the exercise of, or is +conditioned on the non-exercise of one or more of the rights that are +specifically granted under this License. You may not convey a covered +work if you are a party to an arrangement with a third party that is +in the business of distributing software, under which you make payment +to the third party based on the extent of your activity of conveying +the work, and under which the third party grants, to any of the +parties who would receive the covered work from you, a discriminatory +patent license (a) in connection with copies of the covered work +conveyed by you (or copies made from those copies), or (b) primarily +for and in connection with specific products or compilations that +contain the covered work, unless you entered into that arrangement, +or that patent license was granted, prior to 28 March 2007. + + Nothing in this License shall be construed as excluding or limiting +any implied license or other defenses to infringement that may +otherwise be available to you under applicable patent law. + + 12. No Surrender of Others' Freedom. + + If conditions are imposed on you (whether by court order, agreement or +otherwise) that contradict the conditions of this License, they do not +excuse you from the conditions of this License. If you cannot convey a +covered work so as to satisfy simultaneously your obligations under this +License and any other pertinent obligations, then as a consequence you may +not convey it at all. For example, if you agree to terms that obligate you +to collect a royalty for further conveying from those to whom you convey +the Program, the only way you could satisfy both those terms and this +License would be to refrain entirely from conveying the Program. + + 13. Use with the GNU Affero General Public License. + + Notwithstanding any other provision of this License, you have +permission to link or combine any covered work with a work licensed +under version 3 of the GNU Affero General Public License into a single +combined work, and to convey the resulting work. The terms of this +License will continue to apply to the part which is the covered work, +but the special requirements of the GNU Affero General Public License, +section 13, concerning interaction through a network will apply to the +combination as such. + + 14. Revised Versions of this License. + + The Free Software Foundation may publish revised and/or new versions of +the GNU General Public License from time to time. Such new versions will +be similar in spirit to the present version, but may differ in detail to +address new problems or concerns. + + Each version is given a distinguishing version number. If the +Program specifies that a certain numbered version of the GNU General +Public License "or any later version" applies to it, you have the +option of following the terms and conditions either of that numbered +version or of any later version published by the Free Software +Foundation. If the Program does not specify a version number of the +GNU General Public License, you may choose any version ever published +by the Free Software Foundation. + + If the Program specifies that a proxy can decide which future +versions of the GNU General Public License can be used, that proxy's +public statement of acceptance of a version permanently authorizes you +to choose that version for the Program. + + Later license versions may give you additional or different +permissions. However, no additional obligations are imposed on any +author or copyright holder as a result of your choosing to follow a +later version. + + 15. Disclaimer of Warranty. + + THERE IS NO WARRANTY FOR THE PROGRAM, TO THE EXTENT PERMITTED BY +APPLICABLE LAW. EXCEPT WHEN OTHERWISE STATED IN WRITING THE COPYRIGHT +HOLDERS AND/OR OTHER PARTIES PROVIDE THE PROGRAM "AS IS" WITHOUT WARRANTY +OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, +THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR +PURPOSE. THE ENTIRE RISK AS TO THE QUALITY AND PERFORMANCE OF THE PROGRAM +IS WITH YOU. SHOULD THE PROGRAM PROVE DEFECTIVE, YOU ASSUME THE COST OF +ALL NECESSARY SERVICING, REPAIR OR CORRECTION. + + 16. Limitation of Liability. + + IN NO EVENT UNLESS REQUIRED BY APPLICABLE LAW OR AGREED TO IN WRITING +WILL ANY COPYRIGHT HOLDER, OR ANY OTHER PARTY WHO MODIFIES AND/OR CONVEYS +THE PROGRAM AS PERMITTED ABOVE, BE LIABLE TO YOU FOR DAMAGES, INCLUDING ANY +GENERAL, SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES ARISING OUT OF THE +USE OR INABILITY TO USE THE PROGRAM (INCLUDING BUT NOT LIMITED TO LOSS OF +DATA OR DATA BEING RENDERED INACCURATE OR LOSSES SUSTAINED BY YOU OR THIRD +PARTIES OR A FAILURE OF THE PROGRAM TO OPERATE WITH ANY OTHER PROGRAMS), +EVEN IF SUCH HOLDER OR OTHER PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF +SUCH DAMAGES. + + 17. Interpretation of Sections 15 and 16. + + If the disclaimer of warranty and limitation of liability provided +above cannot be given local legal effect according to their terms, +reviewing courts shall apply local law that most closely approximates +an absolute waiver of all civil liability in connection with the +Program, unless a warranty or assumption of liability accompanies a +copy of the Program in return for a fee. + + END OF TERMS AND CONDITIONS + + How to Apply These Terms to Your New Programs + + If you develop a new program, and you want it to be of the greatest +possible use to the public, the best way to achieve this is to make it +free software which everyone can redistribute and change under these terms. + + To do so, attach the following notices to the program. It is safest +to attach them to the start of each source file to most effectively +state the exclusion of warranty; and each file should have at least +the "copyright" line and a pointer to where the full notice is found. + + + Copyright (C) + + This program is free software: you can redistribute it and/or modify + it under the terms of the GNU General Public License as published by + the Free Software Foundation, either version 3 of the License, or + (at your option) any later version. + + This program is distributed in the hope that it will be useful, + but WITHOUT ANY WARRANTY; without even the implied warranty of + MERCHANTABILITY or FITNESS FOR A PARTICULAR PURPOSE. See the + GNU General Public License for more details. + + You should have received a copy of the GNU General Public License + along with this program. If not, see . + +Also add information on how to contact you by electronic and paper mail. + + If the program does terminal interaction, make it output a short +notice like this when it starts in an interactive mode: + + Copyright (C) + This program comes with ABSOLUTELY NO WARRANTY; for details type `show w'. + This is free software, and you are welcome to redistribute it + under certain conditions; type `show c' for details. + +The hypothetical commands `show w' and `show c' should show the appropriate +parts of the General Public License. Of course, your program's commands +might be different; for a GUI interface, you would use an "about box". + + You should also get your employer (if you work as a programmer) or school, +if any, to sign a "copyright disclaimer" for the program, if necessary. +For more information on this, and how to apply and follow the GNU GPL, see +. + + The GNU General Public License does not permit incorporating your program +into proprietary programs. If your program is a subroutine library, you +may consider it more useful to permit linking proprietary applications with +the library. If this is what you want to do, use the GNU Lesser General +Public License instead of this License. But first, please read +. diff --git a/README.txt b/README.txt new file mode 100644 index 0000000..90a493b --- /dev/null +++ b/README.txt @@ -0,0 +1,72 @@ + PDosage + ======= + +What is PDosage? +---------------- + +PDosage is a web application for calculating dosage of some commonly +used drugs. Although it's primarily designed for the practice of +Pediatrics, it also provides adult doses of drugs, making it useful +for other disciplines too. + +PDosage is written in Javascript. + +Downloading +----------- + +Latest release of PDosage can be downloaded from +https://code.agnibho.com/PDosage/ + +The source code is available at https://github.com/agnibho/pdosage/ + +Usage +----- + +PDosage needs to be compiled before in can be used. You need Node.js +and npm installed in your system to compile PDosage. + +After downloading and decompressing the package, enter the package +directory and issue the following commands: + +npm install +npm run build + +Now you can use the app by opening the index.html file in any modern +web browser. + +Alternatively you can run a development version of the app by issuing- + +npm run dev + +The interface of the application is designed to be self-explanatory. + +A hosted version of PDosage is available at +https://app.agnibho.com/pdosage/ + +Licensing +--------- + +Copyright (c) 2016 Agnibho Mondal +All rights reserved + +This file is part of PDosage. + +PDosage is free software: you can redistribute it and/or modify it +under the terms of the GNU General Public License as published by the +Free Software Foundation, either version 3 of the License, or (at your +option) any later version. + +PDosage is distributed in the hope that it will be useful, but WITHOUT +ANY WARRANTY; without even the implied warranty of MERCHANTABILITY or +FITNESS FOR A PARTICULAR PURPOSE. See the GNU General Public License +for more details. + +You should have received a copy of the GNU General Public License +along with PDosage. If not, see . + +Contacts +-------- + +Agnibho Mondal +mail@agnibho.com +www.agnibho.com diff --git a/index.html b/index.html new file mode 100755 index 0000000..77a01d7 --- /dev/null +++ b/index.html @@ -0,0 +1,97 @@ + + + + + PDosage + + + + + + + +
+ + + + diff --git a/package.json b/package.json new file mode 100644 index 0000000..053d4c5 --- /dev/null +++ b/package.json @@ -0,0 +1,31 @@ +{ + "name": "pdosage", + "description": "Pediatric Dose Calculator", + "author": "Agnibho Mondal ", + "private": true, + "scripts": { + "predev": "node ./prepare.js", + "dev": "cross-env NODE_ENV=development webpack-dev-server --open --inline --hot", + "prebuild": "node ./prepare.js", + "build": "cross-env NODE_ENV=production webpack --progress --hide-modules" + }, + "dependencies": { + "vue": "^2.0.1" + }, + "devDependencies": { + "babel-core": "^6.0.0", + "babel-loader": "^6.0.0", + "babel-preset-es2015": "^6.0.0", + "cross-env": "^3.0.0", + "css-loader": "^0.25.0", + "style-loader": "^0.13.1", + "file-loader": "^0.9.0", + "json-loader": "^0.5.4", + "vue-loader": "^9.7.0", + "jquery":"^3.1.1", + "bootstrap": "^3.3.7", + "bootstrap-validator": "^0.11.5", + "webpack": "^2.1.0-beta.25", + "webpack-dev-server": "^2.1.0-beta.0" + } +} diff --git a/prepare.js b/prepare.js new file mode 100644 index 0000000..89f2a67 --- /dev/null +++ b/prepare.js @@ -0,0 +1,28 @@ +var DATA_SRC="./src/data/"; +var DATA_FILE="./src/dosage.json"; +var fs=require("fs"); + +if(process.argv[2]=="watch"){ + fs.watch(DATA_SRC, jsonCat); +} +else{ + jsonCat(); +} + +function jsonCat(){ + console.log("Joining JSON data files"); + var bigData=[] + var files=fs.readdirSync(DATA_SRC); + for(var i=0; i. +*********************************************************************** +--> + + + diff --git a/src/CalculatorView.vue b/src/CalculatorView.vue new file mode 100644 index 0000000..1d4d885 --- /dev/null +++ b/src/CalculatorView.vue @@ -0,0 +1,102 @@ + + + + diff --git a/src/DataInput.vue b/src/DataInput.vue new file mode 100644 index 0000000..9ac78aa --- /dev/null +++ b/src/DataInput.vue @@ -0,0 +1,123 @@ + + + + diff --git a/src/DrugView.vue b/src/DrugView.vue new file mode 100644 index 0000000..3ba5928 --- /dev/null +++ b/src/DrugView.vue @@ -0,0 +1,129 @@ + + + + diff --git a/src/ListView.vue b/src/ListView.vue new file mode 100644 index 0000000..f8f14d8 --- /dev/null +++ b/src/ListView.vue @@ -0,0 +1,75 @@ + + + + diff --git a/src/QuickView.vue b/src/QuickView.vue new file mode 100644 index 0000000..e18482f --- /dev/null +++ b/src/QuickView.vue @@ -0,0 +1,84 @@ + + + + diff --git a/src/assets/logo.png b/src/assets/logo.png new file mode 100644 index 0000000..18c275a Binary files /dev/null and b/src/assets/logo.png differ diff --git a/src/custom.css b/src/custom.css new file mode 100755 index 0000000..618367d --- /dev/null +++ b/src/custom.css @@ -0,0 +1,31 @@ +/********************************************************************** + * Title: PDosage + * Description: Pediatric Dose Calculator + * Author: Agnibho Mondal + * Website: http://code.agnibho.com + ********************************************************************** + Copyright (c) 2016 Agnibho Mondal + All rights reserved + ********************************************************************** + This file is part of PDosage. + + PDosage is free software: you can redistribute it and/or modify + it under the terms of the GNU General Public License as published by + the Free Software Foundation, either version 3 of the License, or + (at your option) any later version. + + PDosage is distributed in the hope that it will be useful, + but WITHOUT ANY WARRANTY; without even the implied warranty of + MERCHANTABILITY or FITNESS FOR A PARTICULAR PURPOSE. See the + GNU General Public License for more details. + + You should have received a copy of the GNU General Public License + along with PDosage. If not, see . + **********************************************************************/ + +h1, h2, h3, h4, h5, h6{ + text-align:center; +} +.clickable{ + cursor:pointer; +} diff --git a/src/data/amikacin.json b/src/data/amikacin.json new file mode 100644 index 0000000..8c3e6e6 --- /dev/null +++ b/src/data/amikacin.json @@ -0,0 +1,77 @@ +{ + "name": "Amikacin", + "form": [ + { + "mode": "Inj", + "gen": true, + "dose": { + "perKg": [ + 15, + 20 + ], + "limit": [ + 1500, + 1500 + ], + "unit": "mg", + "txt": "IM or IV per day q 8-12 hr", + "comment": "infusion over 1 hr" + } + }, + { + "mode": "Inj", + "content": "100mg", + "dose": { + "approx": [ + 100, + "15*bw", + "20*bw" + ], + "limit": [ + 15, + 15 + ], + "unit": "vial", + "txt": "", + "comment": "" + } + }, + { + "mode": "Inj", + "content": "250mg", + "dose": { + "approx": [ + 250, + "15*bw", + "20*bw" + ], + "limit": [ + 6, + 6 + ], + "unit": "vial", + "txt": "", + "comment": "" + } + }, + { + "mode": "Inj", + "content": "500mg", + "dose": { + "approx": [ + 500, + "15*bw", + "20*bw" + ], + "limit": [ + 3, + 3 + ], + "unit": "vial", + "txt": "", + "comment": "" + } + } + ], + "comment": "Adjust dose in renal failure." +} diff --git a/src/data/amoxycillin_clavulinic_acid.json b/src/data/amoxycillin_clavulinic_acid.json new file mode 100644 index 0000000..87e319b --- /dev/null +++ b/src/data/amoxycillin_clavulinic_acid.json @@ -0,0 +1,155 @@ +{ + "name": "Amoxycillin / Clavulinic Acid", + "form": [ + { + "mode": "Oral", + "gen": true, + "dose": { + "perKg": [ + 25, + 50 + ], + "limit": [ + 250, + 500 + ], + "unit": "mg", + "txt": "q 8-12 hr" + } + }, + { + "mode": "IV", + "gen": true, + "dose": { + "perKg": [ + 50, + 100 + ], + "limit": [ + 1200, + 1200 + ], + "unit": "mg", + "txt": "q 6-8 hr" + } + }, + { + "mode": "Tab", + "content":"375mg", + "dose": { + "approx": [ + 250, + "25*bw", + "50*bw" + ], + "limit": [ + 1, + 2 + ], + "unit": "tab", + "txt": "" + } + }, + { + "mode": "Tab", + "content":"625mg", + "dose": { + "approx": [ + 500, + "25*bw", + "50*bw" + ], + "limit": [ + 0.5, + 1 + ], + "unit": "tab", + "txt": "" + } + }, + { + "mode": "Syr", + "content":"156mg/5ml", + "dose": { + "perKg": [ + 1, + 2 + ], + "limit": [ + 10, + 20 + ], + "unit": "ml", + "txt": "" + } + }, + { + "mode": "IV", + "content":"150mg", + "dose": { + "approx": [ + 125, + "50*bw", + "100*bw" + ], + "limit": [ + 8, + 8 + ], + "unit": "amp", + "txt": "" + } + }, + { + "mode": "IV", + "content":"300mg", + "dose": { + "approx": [ + 250, + "50*bw", + "100*bw" + ], + "limit": [ + 4, + 4 + ], + "unit": "amp", + "txt": "" + } + }, + { + "mode": "IV", + "content":"600mg", + "dose": { + "approx": [ + 500, + "50*bw", + "100*bw" + ], + "limit": [ + 2, + 2 + ], + "unit": "amp", + "txt": "" + } + }, + { + "mode": "IV", + "content":"1.2gm", + "dose": { + "approx": [ + 1000, + "50*bw", + "100*bw" + ], + "limit": [ + 1, + 1 + ], + "unit": "amp", + "txt": "" + } + } + ] +} diff --git a/src/data/cefixime.json b/src/data/cefixime.json new file mode 100644 index 0000000..69f4c5d --- /dev/null +++ b/src/data/cefixime.json @@ -0,0 +1,32 @@ +{ + "name": "Cefixime", + "form": [ + { + "mode": "Oral", + "gen": true, + "dose": { + "perKg": 8, + "limit": [ + 400, + 400 + ], + "unit": "mg", + "txt": "OD or BD" + } + }, + { + "mode": "Oral", + "gen": true, + "dose": { + "perKg": 20, + "limit": [ + 400, + 400 + ], + "unit": "mg", + "txt": "OD or BD", + "comment": "for enteric fever" + } + } + ] +} diff --git a/src/data/ceftriaxone.json b/src/data/ceftriaxone.json new file mode 100644 index 0000000..39bcb20 --- /dev/null +++ b/src/data/ceftriaxone.json @@ -0,0 +1,63 @@ +{ + "name": "Ceftriaxone", + "form": [ + { + "mode": "Inj", + "gen": true, + "dose": { + "perKg": [ + 50, + 75 + ], + "limit": [ + 1000, + 1000 + ], + "unit": "mg", + "txt": "IV q 12-24 hr" + } + }, + { + "mode": "Inj", + "dose": { + "perKg": 50, + "limit": [ + 1000, + 1000 + ], + "unit": "mg", + "txt": "IV q 12 hr", + "comment": "for Meningitis. Max 4 gm." + } + }, + { + "mode": "Inj", + "range": [ + { + "max": "1y", + "dose": { + "perKg": [ + 25, + 50 + ], + "limit": [ + 125, + 125 + ], + "unit": "mg", + "txt": "single IM or IV for gonococcal ophthalmia neonatoram." + } + } + ] + }, + { + "mode": "Inj", + "dose": { + "val": 125, + "unit": "mg", + "txt": "single IM", + "comment": "prophylaxis for N. meningitidis." + } + } + ] +} diff --git a/src/data/domperidone.json b/src/data/domperidone.json new file mode 100644 index 0000000..798262c --- /dev/null +++ b/src/data/domperidone.json @@ -0,0 +1,87 @@ +{ + "name": "Domperidone", + "form": [ + { + "mode": "Oral", + "gen": true, + "dose": { + "perKg": [ + 0.2, + 0.4 + ], + "limit": [ + 10, + 20 + ], + "unit": "mg", + "txt": "q 4-8 hr" + } + }, + { + "mode": "Tab", + "content": "10mg", + "dose": { + "approx": [ + 10, + "0.2*bw", + "0.4*bw" + ], + "limit": [ + 1, + 2 + ], + "unit": "tab", + "txt": "q 4-8 hr" + } + }, + { + "mode": "Tab", + "content": "5mg", + "dose": { + "approx": [ + 5, + "0.2*bw", + "0.4*bw" + ], + "limit": [ + 2, + 4 + ], + "unit": "tab", + "txt": "q 4-8 hr" + } + }, + { + "mode": "Susp", + "content": "5mg/5ml", + "dose": { + "perKg": [ + 0.2, + 0.4 + ], + "limit": [ + 10, + 20 + ], + "unit": "ml", + "txt": "q 4-8 hr" + } + }, + { + "mode": "Drop", + "content": "10mg/ml", + "dose": { + "perKg": [ + 0.02, + 0.04 + ], + "limit": [ + 1, + 2 + ], + "unit": "ml", + "txt": "q 4-8 hr" + } + } + ] +} diff --git a/src/data/drotaverine.json b/src/data/drotaverine.json new file mode 100644 index 0000000..0062499 --- /dev/null +++ b/src/data/drotaverine.json @@ -0,0 +1,206 @@ +{ + "name": "Drotaverine", + "form": [ + { + "mode": "Oral", + "gen": true, + "range": [ + { + "min": "1y", + "max": "6y", + "dose": { + "val": 20, + "unit": "mg", + "txt": "TDS" + } + }, + { + "min": "6y", + "max": "12y", + "dose": { + "val": 40, + "unit": "mg", + "txt": "TDS" + } + }, + { + "min": "12y", + "dose": { + "val": [ + 40, + 80 + ], + "unit": "mg", + "txt": "TDS" + } + } + ] + }, + { + "mode": "Inj", + "gen": true, + "range": [ + { + "min": "1y", + "max": "6y", + "dose": { + "val": 20, + "unit": "mg", + "txt": "" + } + }, + { + "min": "6y", + "max": "12y", + "dose": { + "val": 40, + "unit": "mg", + "txt": "" + } + }, + { + "min": "12y", + "dose": { + "val": [ + 40, + 80 + ], + "unit": "mg", + "txt": "" + } + } + ] + }, + { + "mode": "Tab", + "content": "40mg", + "range": [ + { + "min": "1y", + "max": "6y", + "dose": { + "val": 0.5, + "unit": "tab", + "txt": "" + } + }, + { + "min": "6y", + "max": "12y", + "dose": { + "val": 1, + "unit": "tab", + "txt": "" + } + }, + { + "min": "12y", + "dose": { + "val": [ + 1, + 2 + ], + "unit": "tab", + "txt": "" + } + } + ] + }, + { + "mode": "Tab", + "content": "80mg", + "range": [ + { + "min": "6y", + "max": "12y", + "dose": { + "val": 0.5, + "unit": "tab", + "txt": "" + } + }, + { + "min": "12y", + "dose": { + "val": [ + 0.5, + 1 + ], + "unit": "tab", + "txt": "" + } + } + ] + }, + { + "mode": "Susp", + "content": "20mg/5ml", + "range": [ + { + "min": "1y", + "max": "6y", + "dose": { + "val": 5, + "unit": "ml", + "txt": "" + } + }, + { + "min": "6y", + "max": "12y", + "dose": { + "val": 2, + "unit": "ml", + "txt": "" + } + }, + { + "min": "12y", + "dose": { + "val": [ + 2, + 4 + ], + "unit": "ml", + "txt": "" + } + } + ] + }, + { + "mode": "Inj", + "content": "20mg/ml", + "range": [ + { + "min": "1y", + "max": "6y", + "dose": { + "val": 1, + "unit": "ml", + "txt": "" + } + }, + { + "min": "6y", + "max": "12y", + "dose": { + "val": 2, + "unit": "ml", + "txt": "" + } + }, + { + "min": "12y", + "dose": { + "val": [ + 2, + 4 + ], + "unit": "tab", + "txt": "" + } + } + ] + } + ] +} diff --git a/src/data/hydroxyzine.json b/src/data/hydroxyzine.json new file mode 100644 index 0000000..7e7f305 --- /dev/null +++ b/src/data/hydroxyzine.json @@ -0,0 +1,143 @@ +{ + "name": "Hydroxyzine", + "form": [ + { + "mode": "Oral", + "gen": true, + "range": [ + { + "min": "6m", + "dose": { + "perKg": 2, + "limit": [ + 50, + 200 + ], + "unit": "mg", + "txt": "per day q 6 hr" + } + } + ] + }, + { + "mode": "IM", + "gen": true, + "range": [ + { + "min": "6m", + "dose": { + "perKg": [ + 0.5, + 1 + ], + "limit": [ + 50, + 200 + ], + "unit": "mg", + "txt": "q 4-6 hr" + } + } + ] + }, + { + "mode": "Tab", + "content": "10mg", + "range": [ + { + "min": "6m", + "dose": { + "approx": [ + 10, + "2*bw" + ], + "limit": [ + 5, + 20 + ], + "unit": "tab", + "txt": "per day q 6 hr" + } + } + ] + }, + { + "mode": "Tab", + "content": "25", + "range": [ + { + "min": "6m", + "dose": { + "approx": [ + 25, + "2*bw" + ], + "limit": [ + 2, + 8 + ], + "unit": "tab", + "txt": "per day q 6 hr" + } + } + ] + }, + { + "mode": "Syr", + "content": "10mg/5ml", + "range": [ + { + "min": "6m", + "dose": { + "perKg": 1, + "limit": [ + 25, + 100 + ], + "unit": "ml", + "txt": "per day q 6 hr" + } + } + ] + }, + { + "mode": "Drop", + "content": "6mg/ml", + "range": [ + { + "min": "6m", + "dose": { + "perKg": 0.33, + "limit": [ + 8.33, + 33.33 + ], + "unit": "ml", + "txt": "per day q 6 hr" + } + } + ] + }, + { + "mode": "IM", + "content": "25mg/ml", + "range": [ + { + "min": "6m", + "dose": { + "perKg": [ + 0.02, + 0.04 + ], + "limit": [ + 2, + 8 + ], + "unit": "ml", + "txt": "" + } + } + ] + } + ] +} diff --git a/src/data/levosalbutamol.json b/src/data/levosalbutamol.json new file mode 100644 index 0000000..72a579c --- /dev/null +++ b/src/data/levosalbutamol.json @@ -0,0 +1,134 @@ +{ + "name": "Levosalbutamol", + "form": [ + { + "mode": "Oral", + "gen": true, + "dose": { + "perKg": [ + 0.05, + 0.2 + ], + "limit": [ + 1, + 2 + ], + "unit": "mg", + "txt": "2-3 times a day" + } + }, + { + "mode": "Tab.", + "content": "1mg", + "dose": { + "approx": [ + 1, + "0.05*bw", + "0.2*bw" + ], + "limit": [ + 1, + 2 + ], + "unit": "tab", + "txt": "2-3 times a day" + } + }, + { + "mode": "Tab.", + "content": "2mg", + "dose": { + "approx": [ + 2, + "0.05*bw", + "0.2*bw" + ], + "limit": [ + 1, + 2 + ], + "unit": "tab", + "txt": "2-3 times a day" + } + }, + { + "mode": "Syr.", + "content": "1mg/5ml", + "dose": { + "perKg": [ + 0.25, + 1 + ], + "limit": [ + 5, + 10 + ], + "unit": "ml", + "txt": "2-3 times a day" + } + }, + { + "mode": "Syr.", + "content": "0.5mg/5ml", + "dose": { + "perKg": [ + 0.5, + 2 + ], + "limit": [ + 10, + 20 + ], + "unit": "ml", + "txt": "2-3 times a day" + } + }, + { + "mode": "Resp.", + "range": [ + { + "min": "2m", + "max": "6m", + "dose": { + "val": "0.31", + "unit": "mg" + } + }, + { + "min": "6m", + "max": "1y", + "dose": { + "val": "0.63", + "unit": "mg" + } + }, + { + "min": "2m", + "dose": { + "val": "1.25", + "unit": "mg" + } + } + ] + }, + { + "mode": "MDI", + "content": "50mcg/puff", + "dose": [ + { + "val": [ + 2, + 4 + ], + "unit": "puffs", + "txt": "upto 3 at 20 mins interval" + }, + { + "val": 2, + "unit": "puffs", + "txt": "every 4-6 hrs following initial Tx" + } + ] + } + ] +} diff --git a/src/data/ofloxacin.json b/src/data/ofloxacin.json new file mode 100644 index 0000000..908a556 --- /dev/null +++ b/src/data/ofloxacin.json @@ -0,0 +1,127 @@ +{ + "name": "Ofloxacin", + "form": [ + { + "mode": "Oral", + "gen": true, + "dose": { + "perKg": 15, + "limit": [ + 400, + 800 + ], + "unit": "mg", + "txt": "per day q 12 hr" + } + }, + { + "mode": "IV", + "gen": true, + "dose": { + "perKg": [ + 5, + 10 + ], + "limit": [ + 400, + 800 + ], + "unit": "mg", + "txt": "per day q 12 hr" + } + }, + { + "mode": "Tab", + "content": "100mg", + "dose": { + "approx": [ + 100, + "15*bw" + ], + "limit": [ + 4, + 8 + ], + "unit": "tab", + "txt": "" + } + }, + { + "mode": "Tab", + "content": "200mg", + "dose": { + "approx": [ + 200, + "15*bw" + ], + "limit": [ + 2, + 4 + ], + "unit": "tab", + "txt": "" + } + }, + { + "mode": "Tab", + "content": "400mg", + "dose": { + "approx": [ + 400, + "15*bw" + ], + "limit": [ + 1, + 2 + ], + "unit": "tab", + "txt": "" + } + }, + { + "mode": "Susp", + "content": "100mg/5ml", + "dose": { + "perKg": 0.75, + "limit": [ + 20, + 40 + ], + "unit": "ml", + "txt": "" + } + }, + { + "mode": "IV", + "content": "200mg/100ml", + "dose": { + "perKg": [ + 2.5, + 5 + ], + "limit": [ + 200, + 400 + ], + "unit": "ml", + "txt": "infusion" + } + }, + { + "mode": "IV", + "content": "400mg/100ml", + "dose": { + "perKg": [ + 1.25, + 2.5 + ], + "limit": [ + 100, + 200 + ], + "unit": "ml", + "txt": "infusion" + } + } + ] +} diff --git a/src/data/ondansetron.json b/src/data/ondansetron.json new file mode 100644 index 0000000..e2cadfe --- /dev/null +++ b/src/data/ondansetron.json @@ -0,0 +1,177 @@ +{ + "name": "Ondansetron", + "form": [ + { + "mode": "Oral", + "gen": true, + "range": [ + { + "min": "3y", + "max": "4y", + "dose": + { + "val": 2, + "unit": "mg", + "txt": "q 4 hr" + } + }, + { + "min": "4y", + "max": "11y", + "dose": + { + "val": 4, + "unit": "mg", + "txt": "q 4 hr" + } + }, + { + "min": "8y", + "dose": + { + "val": 8, + "unit": "mg", + "txt": "q 4 hr" + } + } + ] + }, + { + "mode": "IV", + "gen": true, + "range": [ + { + "min": "3y", + "dose": { + "perKg": [ + 0.15, + 0.45 + ], + "limit": [ + 8, + 8 + ], + "unit": "mg", + "txt": "q 4 hr slow IV" + } + } + ] + }, + { + "mode": "Tab", + "content": "4", + "range": [ + { + "min": "3y", + "max": "4y", + "dose": + { + "val": 0.5, + "unit": "tab", + "txt": "q 4 hr" + } + }, + { + "min": "4y", + "max": "11y", + "dose": + { + "val": 1, + "unit": "tab", + "txt": "q 4 hr" + } + }, + { + "min": "8y", + "dose": + { + "val": 2, + "unit": "tab", + "txt": "q 4 hr" + } + } + ] + }, + { + "mode": "Tab", + "content": "8mg", + "range": [ + { + "min": "4y", + "max": "11y", + "dose": + { + "val": 0.5, + "unit": "tab", + "txt": "q 4 hr" + } + }, + { + "min": "8y", + "dose": + { + "val": 1, + "unit": "tab", + "txt": "q 4 hr" + } + } + ] + }, + { + "mode": "Syr", + "content": "2mg/5ml", + "range": [ + { + "min": "3y", + "max": "4y", + "dose": + { + "val": 5, + "unit": "ml", + "txt": "q 4 hr" + } + }, + { + "min": "4y", + "max": "11y", + "dose": + { + "val": 10, + "unit": "ml", + "txt": "q 4 hr" + } + }, + { + "min": "8y", + "dose": + { + "val": 20, + "unit": "ml", + "txt": "q 4 hr" + } + } + ] + }, + { + "mode": "IV", + "content": "2mg/ml", + "range": [ + { + "min": "3y", + "dose": { + "perKg": [ + 0.08, + 0.22 + ], + "limit": [ + 4, + 4 + ], + "unit": "ml", + "txt": "q 4 hr slow IV" + } + } + ] + } + ] +} diff --git a/src/data/paracetamol.json b/src/data/paracetamol.json new file mode 100644 index 0000000..59d157f --- /dev/null +++ b/src/data/paracetamol.json @@ -0,0 +1,218 @@ +{ + "name": "Paracetamol", + "form": [ + { + "mode": "Oral", + "gen": true, + "dose": [ + { + "perKg": [ + 15, + 15 + ], + "limit": [ + 500, + 1000 + ], + "unit": "mg", + "txt": "q 4-6 hr" + }, + { + "perKg": 60, + "limit": [ + 4000, + 4000 + ], + "unit": "mg", + "txt": "maximum in 24 hrs" + } + ] + }, + { + "mode": "Rectal", + "gen": true, + "dose": { + "perKg": [ + 15, + 15 + ], + "limit": [ + 500, + 1000 + ], + "unit": "mg", + "txt": "" + } + }, + { + "mode": "IM", + "gen": true, + "dose": { + "perKg": [ + 5, + 5 + ], + "limit": [ + 500, + 1000 + ], + "unit": "mg", + "txt": "" + } + }, + { + "mode": "Tab", + "content":"500mg", + "dose": { + "approx": [ + 500, + "15*bw", + "15*bw" + ], + "limit": [ + 1, + 2 + ], + "unit": "tab", + "txt": "" + } + }, + { + "mode": "Tab", + "content":"650mg", + "dose": { + "approx": [ + 650, + "15*bw", + "15*bw" + ], + "limit": [ + 1, + 1.5 + ], + "unit": "tab", + "txt": "" + } + }, + { + "mode": "Tab", + "content":"250mg", + "dose": { + "approx": [ + 250, + "15*bw", + "15*bw" + ], + "limit": [ + 2, + 4 + ], + "unit": "tab", + "txt": "" + } + }, + { + "mode": "Tab", + "content":"1000mg", + "dose": { + "approx": [ + 1000, + "15*bw", + "15*bw" + ], + "limit": [ + 1, + 1 + ], + "unit": "tab", + "txt": "" + } + }, + { + "mode": "Syr", + "content":"125mg/5ml", + "dose": { + "perKg": 0.6, + "limit": [ + 20, + 40 + ], + "unit": "ml", + "txt": "" + } + }, + { + "mode": "Syr", + "content":"250mg/5ml", + "dose": { + "perKg": 0.3, + "limit": [ + 10, + 20 + ], + "unit": "ml", + "txt": "" + } + }, + { + "mode": "Drop", + "content":"100mg/ml", + "dose": { + "perKg": 0.15, + "limit": [ + 5, + 10 + ], + "unit": "ml", + "txt": "" + } + }, + { + "mode": "Rectal", + "content":"125mg", + "dose": { + "approx": [ + 125, + "15*bw", + "15*bw" + ], + "limit": [ + 4, + 8 + ], + "unit": "suppositories", + "txt": "" + } + }, + { + "mode": "Rectal", + "content":"250mg", + "dose": { + "approx": [ + 250, + "15*bw", + "15*bw" + ], + "limit": [ + 2, + 4 + ], + "unit": "suppositories", + "txt": "" + } + }, + { + "mode": "IM", + "content":"150mg/5ml", + "dose": { + "perKg": 0.03, + "limit": [ + 3, + 6.5 + ], + "unit": "ml", + "txt": "" + } + } + ] +} diff --git a/src/data/ranitidine.json b/src/data/ranitidine.json new file mode 100644 index 0000000..52cfd13 --- /dev/null +++ b/src/data/ranitidine.json @@ -0,0 +1,120 @@ +{ + "name": "Ranitidine", + "form": [ + { + "mode": "Oral", + "gen": true, + "dose": { + "perKg": [ + 2, + 4 + ], + "limit": [ + 300, + 300 + ], + "unit": "mg", + "txt": "per day" + } + }, + { + "mode": "Oral", + "gen": true, + "dose": { + "perKg": [ + 4, + 8 + ], + "limit": [ + 600, + 600 + ], + "unit": "mg", + "txt": "per day", + "comment": "in GERD (double dose)" + } + }, + { + "mode": "Inj", + "gen": true, + "dose": { + "perKg": [ + 1, + 2 + ], + "limit": [ + 200, + 200 + ], + "unit": "mg", + "txt": "IV per day" + } + }, + { + "mode": "Tab", + "content": "150mg", + "dose": { + "approx": [ + 150, + "2*bw", + "4*bw" + ], + "limit": [ + 2, + 2 + ], + "unit": "tab", + "txt": "per day" + } + }, + { + "mode": "Tab", + "content": "300mg", + "dose": { + "approx": [ + 300, + "2*bw", + "4*bw" + ], + "limit": [ + 1, + 1 + ], + "unit": "tab", + "txt": "per day" + } + }, + { + "mode": "Syr", + "content": "75mg/5ml", + "dose": { + "perKg": [ + 0.13, + 0.26 + ], + "limit": [ + 20, + 20 + ], + "unit": "ml", + "txt": "per day" + } + }, + { + "mode": "Inj", + "content": "50mg/2ml", + "dose": { + "perKg": [ + 0.04, + 0.08 + ], + "limit": [ + 8, + 8 + ], + "unit": "ml", + "txt": "IV per day" + } + } + ] +} diff --git a/src/data/zinc.json b/src/data/zinc.json new file mode 100644 index 0000000..81847ac --- /dev/null +++ b/src/data/zinc.json @@ -0,0 +1,58 @@ +{ + "name": "Zinc", + "form": [ + { + "mode": "Oral", + "gen": true, + "range" : [ + { + "max": "1y", + "dose": { + "perKg": 0.5, + "unit": "mg", + "txt": "per day", + "comment": "for deficiency" + } + } + ] + }, + { + "mode": "Oral", + "gen": true, + "range" : [ + { + "max": "6m", + "dose": { + "val": 10, + "unit": "mg", + "txt": "per day", + "comment": "for acute and persistent diarrhea > 14 days" + } + }, + { + "min": "6m", + "dose": { + "val": 20, + "unit": "mg", + "txt": "per day", + "comment": "for acute and persistent diarrhea > 14 days" + } + } + ] + }, + { + "mode": "Oral", + "gen": true, + "dose": { + "perKg": 6, + "limit": [ + 220, + 220 + ], + "unit": "mg", + "txt": "per day", + "comment": "for acrodermatitis" + } + } + ] +} diff --git a/src/dosage.js b/src/dosage.js new file mode 100644 index 0000000..9d7c15c --- /dev/null +++ b/src/dosage.js @@ -0,0 +1,210 @@ +/********************************************************************** + * Title: PDosage + * Description: Pediatric Calculator + * Author: Agnibho Mondal + * Website: http://code.agnibho.com + ********************************************************************** + Copyright (c) 2016 Agnibho Mondal + All rights reserved + ********************************************************************** + This file is part of PDosage. + + PDosage is free software: you can redistribute it and/or modify + it under the terms of the GNU General Public License as published by + the Free Software Foundation, either version 3 of the License, or + (at your option) any later version. + + PDosage is distributed in the hope that it will be useful, + but WITHOUT ANY WARRANTY; without even the implied warranty of + MERCHANTABILITY or FITNESS FOR A PARTICULAR PURPOSE. See the + GNU General Public License for more details. + + You should have received a copy of the GNU General Public License + along with PDosage. If not, see . + **********************************************************************/ + +export default function Dosage(data){ + + Object.defineProperty(data, "prop", { + writable: false + }); + + this.get=function(){ + return data; + } + + this.listDrugs=function(){ + var list=data.map(function(obj){ + return obj.name; + }); + return list; + } + + this.getDrug=function(name, patient){ + if(this.listDrugs().indexOf(name)==-1){ + return null; + } + var drug=JSON.parse(JSON.stringify(data.filter(extract)[0])); + function extract(obj){ + return (obj.name == name); + } + for(var i=0; i=min && patient.wt=min && pDays>"+JSON.stringify(dose)); + if(dose.limit && dose.val){ + if(dose.val[0]>dose.limit[0]){ + dose.val[0]=dose.limit[0]; + } + if(dose.val[1]>dose.limit[1]){ + dose.val[1]=dose.limit[1]; + } + } + if(dose.val[1]==dose.val[0]){ + dose.val[1]=null; + } + return dose; + } + } +} diff --git a/src/main.js b/src/main.js new file mode 100644 index 0000000..914247c --- /dev/null +++ b/src/main.js @@ -0,0 +1,82 @@ +/********************************************************************** + * Title: PDosage + * Description: Pediatric Dose Calculator + * Author: Agnibho Mondal + * Website: http://code.agnibho.com + ********************************************************************** + Copyright (c) 2016 Agnibho Mondal + All rights reserved + ********************************************************************** + This file is part of PDosage. + + PDosage is free software: you can redistribute it and/or modify + it under the terms of the GNU General Public License as published by + the Free Software Foundation, either version 3 of the License, or + (at your option) any later version. + + PDosage is distributed in the hope that it will be useful, + but WITHOUT ANY WARRANTY; without even the implied warranty of + MERCHANTABILITY or FITNESS FOR A PARTICULAR PURPOSE. See the + GNU General Public License for more details. + + You should have received a copy of the GNU General Public License + along with PDosage. If not, see . + **********************************************************************/ + +//Icon +import "./assets/logo.png" + +//CSS +import "bootstrap/dist/css/bootstrap.css"; +import "./custom.css"; + +//JS libs +import "jquery"; +import "bootstrap"; +import "bootstrap-validator"; + +//Backend files +import Dosage from "./dosage.js"; +import data from "./dosage.json"; + +//Vue Components +import Vue from "vue"; +import DataInput from "./DataInput.vue"; +import QuickView from "./QuickView.vue"; +import ListView from "./ListView.vue"; +import CalculatorView from "./CalculatorView.vue"; +import AboutView from "./AboutView.vue"; + +//Start app +var dosage=new Dosage(data); +new Vue({ + el: "#app", + components: { + "data-input": DataInput, + "quick-view": QuickView, + "list-view": ListView, + "calculator-view": CalculatorView, + "about-view": AboutView + }, + data: { + patient: {age: {y:null, m:null, d:null}, wt:null}, + dosage: dosage, + favs: "[]" + }, + created:function(){ + try{ + this.favs=JSON.parse(localStorage.getItem("pdosage_favs")); + } + finally{ + if(this.favs==null){ + this.favs=["Paracetamol", "Levosalbutamol", "Domperidone", "Drotaverine", "Ranitidine"]; + } + } + } +}); + +//Routine jobs +import "./routine.js"; + +//Source Map +//#sourceMappingURL=dist/bundle.js.map diff --git a/src/routine.js b/src/routine.js new file mode 100644 index 0000000..26f2aef --- /dev/null +++ b/src/routine.js @@ -0,0 +1,69 @@ +/********************************************************************** + * Title: PDosage + * Description: Pediatric Calculator + * Author: Agnibho Mondal + * Website: http://code.agnibho.com + ********************************************************************** + Copyright (c) 2016 Agnibho Mondal + All rights reserved + ********************************************************************** + This file is part of PDosage. + + PDosage is free software: you can redistribute it and/or modify + it under the terms of the GNU General Public License as published by + the Free Software Foundation, either version 3 of the License, or + (at your option) any later version. + + PDosage is distributed in the hope that it will be useful, + but WITHOUT ANY WARRANTY; without even the implied warranty of + MERCHANTABILITY or FITNESS FOR A PARTICULAR PURPOSE. See the + GNU General Public License for more details. + + You should have received a copy of the GNU General Public License + along with PDosage. If not, see . + **********************************************************************/ + +$(document).ready(function(){ + + //Remove loader + $(".loader").remove(); + $(".container").fadeIn(); + + //Update copyright + $(".copyright").each(function(){ + if(new Date().getFullYear()>$(this).data("start")){ + $(this).text($(this).data("start")+"-"+new Date().getFullYear()); + } + else{ + $(this).text(new Date().getFullYear()); + } + }); + + //Emit input on form reset + $("input[type='reset']").on("click", function(e){ + this.form.reset(); + $(this.form).find("input, select, textarea").each(function(){ + this.dispatchEvent(new Event("input")); + }); + }); + + //Change focus after number input + $(".jump-focus").on("input", function(){ + if($(this).val().length == $(this).prop("maxlength")){ + var all=$("input").toArray(); + var i=all.indexOf(this)+1; + $(all[i]).focus().select(); + } + }); + + //Defocus after input finished + $(".stop-focus").on("input", function(){ + if($(this).val().length == $(this).prop("maxlength")){ + $(this).blur(); + var target=$($(this).data("ref")); + $("html, body").animate({ + scrollTop: $(target).offset().top + }, 1000); + } + }); +}); diff --git a/webpack.config.js b/webpack.config.js new file mode 100644 index 0000000..d87f3b8 --- /dev/null +++ b/webpack.config.js @@ -0,0 +1,80 @@ +var path = require('path') + var webpack = require('webpack') + + module.exports = { + entry: './src/main.js', + output: { + path: path.resolve(__dirname, 'dist'), + publicPath: 'dist/', + filename: 'bundle.js' + }, + module: { + rules: [ + { + test: /\.vue$/, + loader: 'vue-loader', + options: { + // vue-loader options go here + } + }, + { + test: /\.js$/, + loader: 'babel-loader?presets=es2015&retainLines=true', + exclude: /node_modules/ + }, + { + test: /\.css$/, + loader: 'style-loader!css-loader' + }, + { + test: /\.(png|jpg|gif|svg|eot|ttf|woff|woff2)$/, + loader: 'file-loader', + options: { + name: '[name].[ext]?[hash]' + } + }, + { + test: /\.json$/, + loader: 'json-loader' + } + ] + }, + resolve: { + alias: { + 'vue$': 'vue/dist/vue', + 'jquery': 'jquery/src/jquery' + } + }, + plugins: [ + new webpack.ProvidePlugin({ + $: 'jquery', + jquery: 'jquery' + }) + ], + devServer: { + historyApiFallback: true, + noInfo: true + }, + devtool: '#eval-source-map' + } + +if (process.env.NODE_ENV === 'production') { + module.exports.devtool = '#source-map' + // http://vue-loader.vuejs.org/en/workflow/production.html + module.exports.plugins = (module.exports.plugins || []).concat([ + new webpack.DefinePlugin({ + 'process.env': { + NODE_ENV: '"production"' + } + }), + new webpack.optimize.UglifyJsPlugin({ + sourceMap: true, + compress: { + warnings: false + } + }), + new webpack.LoaderOptionsPlugin({ + minimize: true + }) + ]) +}